FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: A systematic review

NuklearMedizin

Volumn 48, Issue 2, 2009, Pages 59-69

  Hellwig, Dirk ^a   Baum, R P ^b   Kirsch, C M ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b ZENTRALKLINIK BAD BERKA   (Germany)

Author keywords

FDG PET; Lung cancer; PET CT; Skeletal scintigraphy; Somatostatin receptor scintigraphy; Systematic review

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM 68; SOMATOSTATIN RECEPTOR;

BONE METASTASIS; BONE SCINTISCANNING; CANCER LOCALIZATION; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FALSE POSITIVE RESULT; GLUCOSE METABOLISM; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SCINTISCANNING; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MEDIASTINUM METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; RADIOISOTOPE DISTRIBUTION; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

CARCINOMA, SMALL CELL; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 66449114915     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0217     Document Type: Review

References (50)

1. nd ed). Chest 2007; 132 (3 Suppl): 1S-19S.
2. Baum RP, Hellwig D, Mezzetti M. Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer. Q J Nucl Med 2004; 48: 119-142. (Pubitemid 39248300)
3. 18F-FDG beim kleinzelligen Lungenkarzinom. Onkologe 2008: 774-782.
4. Baum RP, Prasad V, Hommann M et al. Receptor PET/CT imaging of neuroendocrine tumors. Recent Results Cancer Res 2008; 170: 225-242.
5. Bini A, Grazia M, Stella F et al. The role of somatostatin receptor scintigraphy (Octreoscan) during follow-up of patients after bronchial carcinoid resection. A prospective study. J Cardiovasc Surg (Torino) 2005; 46: 318-319. (Pubitemid 43932998)
6. Birim O, Kappetein AP, Stijnen T et al. Metaanalysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg 2005; 79: 375-382. (Pubitemid 40037519)
7. 18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004; 31: 1614-1620.
8. Cerfolio RJ, Ojha B, Bryant AS et al. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 2004; 78: 1017-1023. (Pubitemid 39164825)
9. DESTATIS. Todesursachen in Deutschland 2007. In: Fachserie 12, Reihe 4. Wiesbaden: Statistisches Bundesamt 2008.
10. nd ed). Chest 2007; 132 (3 Suppl): 202S-220S.
11. Earnest Ft, Ryu JH, Miller GM et al. Suspected non-small cell lung cancer: incidence of occult brain and skeletal metastases and effectiveness of imaging for detection - pilot study. Radiology 1999; 211: 137-145. (Pubitemid 29161743)
12. Fischer BM, Mortensen J, Hojgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol 2001; 2: 659-666. (Pubitemid 33085811)
13. Fischer BM, Mortensen J, Langer SW et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol 2007; 18: 338-345. (Pubitemid 46323103)
14. Giraud P, De Rycke Y, Lavole A et al. Probability of mediastinal involvement in non-small-cell lung cancer: a statistical definition of the clinical target volume for 3-dimensional conformal radiotherapy? Int J Radiat Oncol Biol Phys 2006; 64: 127-135.
15. Gould MK, Kuschner WG, Rydzak CE et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003; 139: 879-892.
16. Gould MK, Maclean CC, Kuschner WG et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001; 285: 914-924. (Pubitemid 32171553)
17. Granberg D, Sundin A, Janson ET et al. Octreoscan in patients with bronchial carcinoid tumours. Clin Endocrinol (Oxf) 2003; 59: 793-799. (Pubitemid 37491586)
18. Grgic A, Nestle U, Schaefer-Schuler A et al. FDG-PET-based radiotherapy planning in lung cancer: Optimum breathing protocol and patient positioning. Int J Radiat Oncol Biol Phys 2008; doi: 10.1016/j.ijrobp.2008.03.063.
19. Griffeth LK, Rich KM, Dehdashti F et al. Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology 1993; 186: 37-44. (Pubitemid 23005464)
20. Halpern BS, Schiepers C, Weber WA et al. Presurgical staging of non-small cell lung cancer: Positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest 2005; 128: 2289-2297. (Pubitemid 41507571)
21. 18F-Fluorodesoxyglukose beim nicht-kleinzelligen Bronchialkarzinom: Bedeutung in der Diagnostik, Therapieplanung und Prognoseabschätzung. Homburg/Saar: Universität des Saarlandes; 2006: 62-80.
22. 18F-FDG PET for mediastinal staging of lung cancer: Which SUV threshold makes sense? J Nucl Med 2007; 48: 1761-1766.
23. Hellwig D, Gröschel A, Graeter TP et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2006; 33: 13-21. (Pubitemid 41785304)
24. 18F-Fluorodesoxyglukose (FDG-PET) bei Lungentumoren. Diskussionsbasis der deutschen Konsensus-Konferenz Onko-PET 2000. Pneumologie 2001; 55: 367-377.
25. 18F] fluorodeoxyglucosepositron emission tomography staging of nonsmall-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 2006; 24: 1800-1806.
26. 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med 2004; 45: 1640-1646.
27. Krause BJ, Beyer T, Bockisch A et al. FDG-PET/CT in oncology. German Guideline. Nuklearmedizin 2007; 46: 291-301.
28. 18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol 2007; 30: 45-50.
29. Lardinois D, Weder W, Hany TF et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348: 2500-2507. (Pubitemid 36706537)
30. MacManus MP, Hicks RJ, Matthews JP et al. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001; 50: 287-293. (Pubitemid 32472257)
31. Marom EM, McAdams HP, Erasmus JJ et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999; 212: 803-809. (Pubitemid 29410986)
32. Mayor S. NICE issues guidance for diagnosis and treatment of lung cancer. Br Med J 2005; 330: 439.
33. Musi M, Carbone RG, Bertocchi C et al. Bronchial carcinoid tumours: a study on clinicopathological features and role of octreotide scintigraphy. Lung Cancer 1998; 22: 97-102. (Pubitemid 29050851)
34. 18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol 2006; 81: 209-225.
35. Niho S, Fujii H, Murakami K et al. Detection of unsuspected distant metastases and/or regional nodes by FDG-PET in LD-SCLC scan in apparent limited-disease small-cell lung cancer. Lung Cancer 2007; 57: 328-333. (Pubitemid 47285426)
36. Nomori H, Watanabe K, Ohtsuka T et al. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. Lung Cancer 2004; 45: 19-27. (Pubitemid 38757828)
37. Palm I, Hellwig D, Leutz M et al. Diagnostische Aussagekraft der Positronenemissionstomographie (PET) bei zerebralen Metastasen von Bronchialkarzinomen. Med Klin 1999; 94: 224-227. (Pubitemid 29213943)
38. Perleth M, Gerhardus A, Velasco-Garrido M. Positronenemissionstomographie: Systematische Übersichten zur Wirksamkeit bei ausgewählten Indikationen. In: Health Technology Assessment, Schriftenreihe des Deutschen Instituts für Medizinische Dokumentation und Information im Auftrag des Bundesministeriums für Gesundheit und Soziale Sicherung. Sankt Augustin: Asgard 2003.
39. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006; 36: 228-247. (Pubitemid 43817847)
40. Shafazand S, Gould MK. A clinical prediction rule to estimate the probability of mediastinal metastasis in patients with non-small cell lung cancer. J Thorac Oncol 2006; 1: 953-959. (Pubitemid 47181362)
41. nd ed). Chest 2007; 132 (3 Suppl): 178S-201S.
42. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003; 123 (1 Suppl): 137S-146S. (Pubitemid 36135711)
43. 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst 2007; 99: 1753-1767.
44. van Tinteren H, Hoekstra OS, Smit EF et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002; 359: 1388-1393.
45. Vansteenkiste J, Fischer BM, Dooms C et al. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004; 5: 531-540. (Pubitemid 39194041)
46. 18F-FDG PET in non-small cell lung cancer. J Nucl Med 2003; 44: 1918-1926.
47. Viney RC, Boyer MJ, King MT et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol 2004; 22: 2357-2362. (Pubitemid 41115392)
48. nd ed). Chest 2007; 132 (3 Suppl): 94S-107S.
49. Weber WA, Dietlein M, Hellwig D et al. PET mit 18F-Fluorodeoxyglukose in der Diagnostik des nicht kleinzelligen Bronchialkarzinoms: evidenzbasierte Empfehlungen und Kosten/Nutzenabwägungen. Nuklearmedizin 2003; 42: 135-144. (Pubitemid 37055549)
50. Yellin A, Zwas ST, Rozenman J et al. Experience with somatostatin receptor scintigraphy in the management of pulmonary carcinoid tumors. Isr Med Assoc J 2005; 7: 712-716. (Pubitemid 41700795)